Cara Therapeutics Inc is an emerging biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, an... Cara Therapeutics Inc is an emerging biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features. 詳細を表示
STAMFORD, Conn., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA) (the “Company”), today announced that a 1-for-12 reverse stock split of its outstanding shares of common...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.485 | -9.26456542502 | 5.235 | 5.5232 | 4.5401 | 69062 | 5.02341195 | CS |
4 | 1.4272 | 42.9517274588 | 3.3228 | 6.36 | 2.7084 | 3942107 | 4.26243132 | CS |
12 | 1.63 | 52.2435897436 | 3.12 | 6.36 | 2.7084 | 1645460 | 4.09629124 | CS |
26 | 1.3336 | 39.035241775 | 3.4164 | 6.36 | 2.7084 | 999394 | 4.0653418 | CS |
52 | -3.2252 | -40.4403651319 | 7.9752 | 13.8 | 2.7084 | 850484 | 5.3441667 | CS |
156 | -136.37 | -96.6340702948 | 141.12 | 167.58 | 2.7084 | 728620 | 45.56920057 | CS |
260 | -181.01 | -97.4429371232 | 185.76 | 355.7676 | 2.7084 | 731015 | 106.00805083 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約